Caplin Point Laboratories’ wholly owned Subsidiary -- Caplin Point Far East, Hong Kong, has executed Share Purchase Agreement (SPA) dated June 03, 2025 for acquiring the entire stake in Triwin Pharma S.A DE C.V, a Mexican Company.
Triwin Pharma shall be the front-end entity for Caplin Point Laboratories in the Mexican market for tender sales, direct sales, marketing and distribution of the products manufactured by Caplin Point Laboratories and its subsidiaries.
Triwin Pharma’s object is to operate in Mexico in the Pharmaceutical Marketing and Distribution business. The acquisition was a strategic decision, as it provides a local partner in Mexico, enabling participation in government tenders and also supporting the establishment of a stock-and-sale model, in line with its successful strategy in other LATAM markets.
Caplin Point Laboratories is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.
